FibroBiologics Expands At-The-Market Equity Offering Capacity

FibroBiologics, Inc. ( (FBLG) ) has shared an update.

FibroBiologics, Inc. disclosed that on May 1, 2026 it entered into an At The Market Offering Agreement with H.C. Wainwright & Co. under which it may issue and sell common stock from time to time pursuant to an existing shelf registration. The ATM Offering is conducted under the company’s Form S-3 registration statement, which was filed on February 3, 2025 and declared effective by the SEC on February 10, 2025, together with a prospectus supplement filed on May 1, 2026.

On May 5, 2026 the company filed an updated prospectus supplement increasing the maximum aggregate offering size under the ATM to $7.5 million, signaling an expanded capacity to raise equity capital as needed. To date, 71,830 shares have been sold under the agreement, and the company also filed its counsel’s legal opinion and consent on the validity of shares issuable, providing additional regulatory clarity and structure for ongoing capital-raising activities.

The most recent analyst rating on (FBLG) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on FibroBiologics, Inc. stock, see the FBLG Stock Forecast page.

Spark’s Take on FBLG Stock

According to Spark, TipRanks’ AI Analyst, FBLG is a Neutral.

The score is held down primarily by weak financial performance (no revenue, widening losses, heavy cash burn) and a strongly bearish technical setup (deeply below key moving averages with negative MACD). Corporate events provide some offset via regained Nasdaq compliance and cost-saving actions, but monitoring/delisting risk and capital structure actions remain notable. Valuation is constrained by a negative P/E and no dividend support.

To see Spark’s full report on FBLG stock, click here.

More about FibroBiologics, Inc.

FibroBiologics, Inc. is a biotechnology company focused on developing and commercializing therapies based on fibroblast cells and related technologies. The company operates in the biopharmaceutical sector and accesses capital markets through equity offerings to support its research, development, and corporate initiatives.

Average Trading Volume: 381,446

Technical Sentiment Signal: Sell

Current Market Cap: $7.19M

Learn more about FBLG stock on TipRanks’ Stock Analysis page.